Synovial Fluid Bank From Arthritic Patients

Establishment of a Bank of Synovial Fluids and Paired Sera From Arthritic Patients for the Evaluation of New Methods Facilitating the Diagnosis and the Monitoring of Progression and Therapy of Arthritis.

The objectives of this group project is to collect synovial fluid (SF) and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.

Study Overview

• Status: Recruiting
• Conditions: Arthritis

Detailed Description

Our group has developed interdisciplinary expertise in biomarkers related to distinct aspects of inflammation-induced joint damage, most notably those associated with degradation of components of the extracellular matrix, bone loss, or associated with post-translational changes on protease inhibitors.

The objectives of this group project is to collect SF and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.

More specifically, we will study (1) biomarkers associated with osteoclastic bone resorption and synthesis/degradation of cartilage, (2) inhibitors of enzymes (calpastatin) that are preferentially targeted by rheumatoid patients, as well as (3) enzymes (e.g. Matrix Metalloproteinases (MMPs)) responsible for the cleavage of components of the articular cartilage.

Finally, we propose to characterize the repertoire of specific active proteases in the SF of arthritic patients concomitantly to the use biomarkers (neoepitopes of cleaved collagens) previously associated with cartilage destruction and synthesis to identify new targets for the development of protease inhibitors for the treatment of arthritis. Furthermore, our project will also provide the opportunity to test the potential of measuring the net proteolytic activity by Fluorescent-Activated Substrate Conversion as a method of monitoring disease activity and treatment efficiency in a clinical setting.

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Gilles Boire, MD, MSc; Phone Number: (819) 564-5261; Email: Gilles.Boire@USherbrooke.ca

Study Locations

• Canada
  • Quebec
    • Sherbrooke, Quebec, Canada, J1H 5N4
      • Recruiting
      • Centre Hospitalier Universitaire de Sherbrooke
      • Contact: Gilles Boire, MD, MSc; Phone Number: (819) 564-5261; Email: Gilles.Boire@USherbrooke.ca
      • Principal Investigator: Gilles Boire, MD, MSc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 95 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

patients suffering from various arthritides (rheumatoid arthritis, gout and other microcristalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic arthritis, and various other diseases, including inflammatory polyarthritis of recent-onset in adults

Description

Inclusion Criteria:

• Significant joint effusion

Exclusion Criteria:

• Hemorrhagic effusion
• Traumatic effusion
• Less than 3 ml total of collected fluid (used for routine analysis and culture)
• Inability or refusal to consent

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Availability of paired synovial fluid and serum samples for exploratory studies	Availability of paired synovial fluid and serum samples, linked with anonymized clinical and treatment data, from patients suffering from various arthritides (rheumatoid arthritis, gout and other microcrystalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic arthritis, and various other diseases, including inflammatory polyarthritis of recent-onset in adults	Use with various collaborators at different times, upon request and approbation

Collaborators and Investigators

• Sponsor: Gilles Boire
• Collaborators: Canadian Arthritis Network
• Investigators: Principal Investigator: Gilles Boire, MD, MSc, CHUS and Université de Sherbrooke

Publications and helpful links

General Publications

• Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, Ghahary A. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007 Aug;34(8):1650-7. Epub 2007 Jul 1.
• Simard N, Boire G, de Brum-Fernandes AJ, St-Pierre Y. A novel approach to measure the contribution of matrix metalloproteinase in the overall net proteolytic activity present in synovial fluids of patients with arthritis. Arthritis Res Ther. 2006;8(4):R125. doi: 10.1186/ar2014.

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2002
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): September 1, 2030

Study Registration Dates

• First Submitted: August 3, 2007
• First Submitted That Met QC Criteria: August 3, 2007
• First Posted (Estimated): August 7, 2007

Study Record Updates

• Last Update Posted (Estimated): December 12, 2023
• Last Update Submitted That Met QC Criteria: December 10, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: Arthritis; Synovial Fluid; Paired serum/synovial fluid samples
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Arthritis
• Other Study ID Numbers: 02-12 LS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO